

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A2

(51) International Patent Classification⁷: C12N 15/11

(21) International Application Number: PCT/US00/22086

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

(71) Applicant (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): INOUE, Roger, T. [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). TORRES-VIERA, Carlos [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas,

Venezuela (VE). MOELLERING, Robert [US/US]; 49 Longfellow Road, Wellesley Hills, MA 02481-5220 (US). GOLD, Howard [US/US]; Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). ELIOPOULOS, George, M. [US/US]; 5 Laurel Circle, Needham, MA 02494 (US).

(74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/12803 A2

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*



(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *vanR*-responsive promoter decoy.